Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Annals of the New York Academy of Sciences

• Publication date

  2011-12-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1111/j.1749-6632.2012.06468.xPMID 22641195PMCID PMC3360579
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database

  2012cited by this paper
• The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.

  2012cited by this paper
• U‐100, pH‐Neutral formulation of VIAject®: faster onset of action than insulin lispro in patients with type 1 diabetes

  2012cited by this paper
• Insulin Glulisine

  2012cited by this paper
• Insulin Degludec in Type 1 Diabetes

  2011cited by this paper
• Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study

  2011cited by this paper
• Effect of cutaneous blood flow on absorption of insulin: a methodological study in healthy male volunteers.

  2011cited by this paper
• Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta‐analysis

  2011cited by this paper
• Conformational Dynamics of Insulin

  2011cited by this paper
• Long-term effects of insulin glargine on the risk of breast cancer

  2011cited by this paper
• Abstracts of the 71st American Diabetes Association Scientific Sessions. June 24-28, 2011. San Diego, California, USA.

  2011cited by this paper
• Intradermal Microneedle Delivery of Insulin Lispro Achieves Faster Insulin Absorption and Insulin Action than Subcutaneous Injection

  2011cited by this paper
• Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

  2011cited by this paper
• Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes

  2011cited by this paper
• A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

  2011cited by this paper
• Improved Pharmacokinetic and Pharmacodynamic Profile of Rapid-Acting Insulin Using Needle-Free Jet Injection Technology

  2011cited by this paper
• Closed-loop insulin delivery for treatment of type 1 diabetes

  2011cited by this paper
• Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion.

  2011cited by this paper
• Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes.

  2011cited by this paper
• Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials

  2011cited by this paper
• Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps.

  2011cited by this paper
• A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes

  2011cited by this paper
• Insulin analogues and cancer risk: the emergence of second-generation studies

  2011cited by this paper
• Long-term effects of intensive glucose lowering on cardiovascular outcomes.

  2011cited by this paper
• Glargine Promotes Proliferation of Breast Adenocarcinoma Cell Line MCF-7 via AKT Activation

  2011cited by this paper
• Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus.

  2010cited by this paper
• Supramolecular Protein Engineering

  2010cited by this paper
• Insulin Glargine and NPH Insulin Increase to a Similar Degree Epithelial Cell Proliferation and Aberrant Crypt Foci Formation in Colons of Diabetic Mice

  2010cited by this paper
• Insulin: a small protein with a long journey

  2010cited by this paper
• Optimal Control of Blood Glucose: The Diabetic Patient or the Machine?

  2010cited by this paper
• Zinc-stapled insulin: Therapeutic application of supramolecular protein engineering

  2010cited by this paper
• An Achilles' Heel in an Amyloidogenic Protein and Its Repair

  2010cited by this paper
• Bioresponsive matrices in drug delivery

  2010cited by this paper
• Virus assembly occurs following a pH- or Ca2+-triggered switch in the thermodynamic attraction between structural protein capsomeres

  2010cited by this paper
• Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

  2010cited by this paper
• Risk of cancer in patients receiving insulin glargine.

  2010cited by this paper
• Insulin Analog Therapy: Improving the Match With Physiologic Insulin Secretion

  2009cited by this paper
• The Discovery of Insulin: Twenty-fifth Anniversary Edition

  2009cited by this paper
• Insulin Glargine: a review 8 years after its introduction

  2009cited by this paper
• Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues

  2009cited by this paper
• Cost-effectiveness of insulin analogues for diabetes mellitus

  2009cited by this paper
• Systematic review and metaanalysis: urinary antigen tests for Legionellosis.

  2009cited by this paper
• Insulin Glulisine: An Evaluation of Its Pharmacodynamic Properties and Clinical Application

  2009cited by this paper
• Chemical synthesis of [des(tetrapeptide B27--30), Tyr(NH2)26-B] and [des(pentapeptide B26--30), Phe(NH2)25-B] bovine insulins.

  2009cited by this paper
• Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.

  2009cited by this paper
• UV cross-linked dextran methacrylate--concanavalin A methacrylamide gel materials for self-regulated insulin delivery.

  2008cited by this paper
• The allosteric role of the Ca2+ switch in adhesion and elasticity of C-cadherin.

  2008cited by this paper
• The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes

  2008cited by this paper
• Is the use of insulin analogues cost-effective?

  2008cited by this paper
• The Structure of a Mutant Insulin Uncouples Receptor Binding from Protein Allostery

  2008cited by this paper
• The global challenge of diabetes.

  2008cited by this paper
• Design of an Active Ultrastable Single-chain Insulin Analog

  2008cited by this paper
• A zinc-dependent adhesion module is responsible for intercellular adhesion in staphylococcal biofilms

  2008cited by this paper
• Intra-Individual Variability of the Metabolic Effect of a Novel Rapid-Acting Insulin (VIAject™) in Comparison to Regular Human Insulin

  2008cited by this paper
• Metallo-supramolecular modules as a paradigm for materials science

  2008cited by this paper
• Protein therapeutics: a summary and pharmacological classification

  2008cited by this paper
• pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity.

  2007cited by this paper
• History of protein crystallography in China

  2007cited by this paper
• Insulin aspart: a review

  2006cited by this paper
• Novel insulin analogues and its mitogenic potential

  2006cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Basal bolus dosing: a clinical experience.

  2005cited by this paper
• Insulin analogues.

  2005cited by this paper
• The global challenge of diabetes.

  2004cited by this paper
• Continuous subcutaneous insulin infusion with short‐acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost‐effectiveness

  2004cited by this paper
• The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

  2004cited by this paper
• Crystallographic and solution studies of N-lithocholyl insulin: a new generation of prolonged-acting human insulins.

  2004cited by this paper
• Systematic characterization of the zinc-finger-containing proteins in the mouse transcriptome.

  2003cited by this paper
• Insulin glulisine. Aventis Pharma.

  2003cited by this paper
• Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta‐analysis

  2003cited by this paper
• Diabetes in Africa. Pathogenesis of type 1 and type 2 diabetes mellitus in sub-Saharan Africa: implications for transitional populations.

  2003cited by this paper
• Pathogenesis of Type 1 and Type 2 Diabetes Mellitus in Sub-Saharan Africa: Implications for Transitional Populations

  2003cited by this paper
• Global epidemic of type 2 diabetes: implications for developing countries.

  2003cited by this paper
• INSULIN GLARGINE (LANTUS®)

  2002cited by this paper
• Emulating biology: Building nanostructures from the bottom up

  2002cited by this paper
• Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics.

  2001cited by this paper
• New perspectives into the molecular pathogenesis and treatment of type 2 diabetes.

  2001cited by this paper
• Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.

  2000cited by this paper
• Implications of the United Kingdom Prospective Diabetes Study (UKPDS) results on patient management.

  2000cited by this paper
• The Discovery of Insulin: The Twenty-fifth Anniversary Edition

  2000cited by this paper
• The lifetime of insulin hexamers.

  1999cited by this paper
• Structure of the alpha beta tubulin dimer by electron crystallography.

  1998cited by this paper
• Self-Association Properties of Monomeric Insulin Analogs Under Formulation Conditions

  1998cited by this paper
• Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro --> Asp insulin analogues.

  1998cited by this paper
• Protein structure : a practical approach

  1997cited by this paper
• The new era of biotech insulin analogues

  1997cited by this paper
• Solution structure of an engineered insulin monomer at neutral pH.

  1996cited by this paper
• Mapping the functional surface of insulin by design: structure and function of a novel A-chain analogue.

  1996cited by this paper
• Structure and dynamics of a protein assembly. 1H-NMR studies of the 36 kDa R6 insulin hexamer.

  1996cited by this paper
• Structure and Dynamics of a Protein Assembly.1H-NMR Studies of the 36 kDaR6Insulin Hexamer

  1996cited by this paper
• Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin.

  1995cited by this paper
• Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I.

  1994cited by this paper
• Receptor binding redefined by a structural switch in a mutant human insulin

  1994cited by this paper
• Insulin structure and stability.

  1993cited by this paper
• Glucokinase as pancreatic beta cell glucose sensor and diabetes gene.

  1993cited by this paper
• The design of metal-binding sites in proteins.

  1993cited by this paper
• Molecular recognition in insulin assembly.

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Action Profile of the Rapid Acting Insulin Analogue: Human Insulin B28Asp

  1993cited by this paper
• Altering the association properties of insulin by amino acid replacement.

  1992cited by this paper

• Biopolymeric Zein Protein Nanoparticles for Oral Vildagliptin Delivery: Fabrication, Statistical Optimization, and In Vivo Pharmacokinetics and Pharmacodynamics Insights

  2026cites this paper
• Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers

  2025cites this paper
• Ionic liquids as stabilisers of therapeutic protein formulations: a review of insulin and monoclonal antibodies

  2024cites this paper
• Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus

  2024cites this paper
• Unraveling Light-Activated Insulin Action in Regulating Blood Glucose: New Photoactivatable Insight as a Novel Modality in Diabetes Management

  2024influential citation
• Nanomaterials for diabetes: diagnosis, detection and delivery

  2024cites this paper
• Se-Glargine I. Chemical Synthesis of a Basal Insulin Analog Stabilized by an Internal Diselenide Bridge

  2023cites this paper
• Carbon nanomaterials: A growing tool for the diagnosis and treatment of diabetes mellitus.

  2023cites this paper
• Se‐Glargine: Chemical Synthesis of a Basal Insulin Analogue Stabilized by an Internal Diselenide Bridge

  2023cites this paper
• Computational prediction of gamma-oryzanol as potential agonist of human peroxisome proliferator-activated receptor gamma (ppar-γ)

  2023cites this paper
• Phytonano particles for the Treatment of Type 2 Diabetes Mellitus: A Review

  2023cites this paper
• Nanomedicine’s transformative impact on anti-diabetic drug discovery: an appraisal

  2023cites this paper
• Insulins for the long term management of diabetes mellitus in dogs: a review

  2022cites this paper
• Enhanced structural stability of insulin aspart in cholinium aminoate ionic liquids.

  2022cites this paper
• Synthesis and Characterization of Phenylboronic Acid-Modified Insulin With Glucose-Dependent Solubility

  2022cites this paper
• Smart erythrocyte-hitchhiking insulin delivery system for prolonged automatic blood glucose control.

  2022cites this paper
• Glucose-responsive erythrocyte-bound nanoparticles for continuously modulated insulin release

  2022cites this paper
• An Overview of Herbal-Based Antidiabetic Drug Delivery Systems: Focus on Lipid- and Inorganic-Based Nanoformulations

  2022cites this paper
• New Horizons: Next-Generation Insulin Analogs: Structural Principles and Clinical Goals.

  2021cites this paper
• Structural and Functional Properties of Proteins

  2021cites this paper
• Structural principles of insulin formulation and analog design: A century of innovation

  2021cites this paper
• Omniligase-1-mediated ligation for insulin analog synthesis in solu-tion and on phage surface

  2021cites this paper
• Efficacy and Safety of Intramuscular Insulin Lispro vs. Continuous Intravenous Regular Insulin for the Treatment of Dogs With Diabetic Ketoacidosis

  2020cites this paper
• Glucose-Responsive Insulin Through Bioconjugation Approaches

  2020cites this paper
• Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy

  2020cites this paper
• Chitosan: A promising therapeutic agent and effective drug delivery system in managing diabetes mellitus.

  2020cites this paper
• Nanotechnology and Diabetes Management: Recent Advances and Future Perspectives

  2020cites this paper
• Long‐Lasting Designer Insulin with Glucose‐Dependent Solubility Markedly Reduces Risk of Hypoglycemia

  2019cites this paper
• Glucose‐Responsive Insulin and Delivery Systems: Innovation and Translation

  2019cites this paper
• Insulin Glargine (IG) : Analog Insulin Kerja-Panjang (Long-Acting)

  2019cites this paper
• Elucidation of the effect of some cholinium amino acid ionic liquids on the thermal and the conformational stability of insulin

  2019cites this paper
• Biologically Inspired and Chemically Derived Methods for Glucose‐Responsive Insulin Therapy

  2019cites this paper
• Display of Single-Chain Insulin-like Peptides on a Yeast Surface.

  2019cites this paper
• Selected Phyto and Marine Bioactive Compounds: Alternatives for the Treatment of Type 2 Diabetes

  2018cites this paper
• Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats.

  2018cites this paper
• Analysis of Insulin Analogs and the Strategy of Their Further Development

  2018cites this paper
• Extreme Adhesion Activity of Amyloid Fibrils Induces Subcutaneous Insulin Resistance

  2018cites this paper
• Biotechnological and Biomedical Applications of Protein Engineering Methods

  2017cites this paper
• Development of a Convenient In Vitro Gel Diffusion Model for Predicting the In Vivo Performance of Subcutaneous Parenteral Formulations of Large and Small Molecules

  2017cites this paper
• Development of a boronic acid sensor-based glucose-responsive nanoparticulate insulin delivery system

  2017cites this paper
• Glucose-responsive insulin by molecular and physical design

  2017cites this paper
• Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes.

  2017cites this paper
• Controlled release of biologics for the treatment of type 2 diabetes.

  2016cites this paper
• Cross-Linked Dependency of Boronic Acid-Conjugated Chitosan Nanoparticles by Diols for Sustained Insulin Release

  2016cites this paper
• Is there an impact of encapsulation on parenteral delivery of insulin

  2016cites this paper
• Synthesis and Identification of FITC-Insulin Conjugates Produced Using Human Insulin and Insulin Analogues for Biomedical Applications

  2016cites this paper
• Degludec: the new ultra-long insulin analogue

  2015cites this paper
• Wnt protein delivery to skeletal stem cells for bone tissue regeneration

  2015cites this paper
• Protein Engineering: Applications to Therapeutic Proteins and Antibodies

  2015cites this paper
• Towards the Era of Biologics and Biosimilars, a Case Of Insulin

  2015cites this paper
• Wyatt Technology Corporation Self-Association of Insulin Quantified by CG-MALS

  2014cites this paper
• Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review

  2014cites this paper
• Managing diabetes with nanomedicine: challenges and opportunities

  2014cites this paper
• Part of the Special Issue: Metabolism 2014 - Alterations of metabolic pathways as therapeutic targets Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARg): a review

  2014cites this paper
• Protein therapeutics (introduction to biopharmaceuticals)

  2013cites this paper
• Design of ultra-stable insulin analogues for the developing world

  2013cites this paper